drugset / Trial / NCT01141881
Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
Terminated
Mashhad University of Medical Sciences
Single-blindTreatment
Summary
Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).
Timeline
- Start
- 2009-05
- Primary completion
- 2010-01
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 25 ug | Intravitreal |
| Background | Bevacizumab | Monoclonal antibody | 1.25 mg | — |